AB Science reports first-half 2026 revenues and activity update

PRESS RELEASE AB SCIENCE REPORTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2026 AND KEY EVENTS OF THE PERIOD -- Change in AB Science's governance and implementation of a new strategy -- Appointment of Stéphane Ledermann as Chairman and Chief Executive Officer -- In-depth overhaul of the Company's organisation and strategy -- Priority given to the development of a new quality assurance system -- Web conference to be held on Wednesday 14 October 2026 at 6:00 pm to present the Company's new ambitions in detail -- Financial and corporate situation -- Operating loss of EUR10.4 million as of 30 June 2026, mainly due to the recognition of a EUR6.5 million provision relating to the Research Tax Credit (Crédit d'Impôt Recherche, CIR) -- Cash position of EUR8.9 million as of 30 June 2026, in addition to which EUR16.5 million was raised through private placements completed in July and August 2026 -- Final agreement on the renegotiation of the repayment terms of its loans with all financial creditors -- Clinical development -- Masitinib: -- Update on the development plan following a sponsor inspection on Good Clinical Practice -- Clinical trial insurance obtained for the Phase 3 study in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) covering up to EUR39 million -- Identification of a potential biomarker to assess the activity of masitinib on the pathological involvement of microglia in Amyotrophic Lateral Sclerosis -- AB8939: -- Update on the Phase 1 study of AB8939 and completion of Stage 3 of Phase 1, evaluating the combination of AB8939 and Venetoclax in the treatment of relapsed or refractory acute myeloid leukaemia Paris, 9 October 2026, 6.15pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces its half-year financial results as of 30 June 2026 and provides an update on its activities. IMPLEMENTATION OF A NEW GOVERNANCE AND A NEW STRATEGY Change in AB Science's governance and appointment of Stéphane Ledermann as Chairman and Chief Executive Officer On 8 July 2026, AB Science announced the decision of its Board of Directors to change the Company's governance in order to enter a new stage of its development, as well as the co-optation of Stéphane Ledermann as Chairman and Chief Executive Officer. The Board of Directors decided to entrust its new Chairman and Chief Executive Officer with conducting a strategic review of the Company's activities, assets and prospects. On this occasion, Mr Alain Moussy, co-founder of AB Science, stepped down from his position as Chairman and Chief Executive Officer and remains a director and shareholder. He no longer holds any other operational role. Implementation of a new organisation and a new ambition Stéphane Ledermann initiated a transformation plan for AB Science as early as 13 July 2026. The main lines of this "Relaunch AB Science" plan were announced to all employees on 2 September 2026 The ambition is now to create value from all of the Company's assets, whatever their